Angiosarcoma Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type (Hemangiosarcoma, Lymphangiosarcoma, Parenchymal Angiosarcoma), By Treatment (Surgery, Radiotherapy, Chemotherapy, Targeted Therapy, Immunotherapy, Others), By End user (Hospital & Clinics, Ambulatory Surgical Centers, Online Pharmacies), By Region and Competition, 2020-2030F

Market Overview

The Global Angiosarcoma Treatment Market , valued at USD 280.11 Million in 2024, is projected to experience a CAGR of 6.11% to reach USD 399.85 Million by 2030. Angiosarcoma treatment encompasses a range of therapeutic strategies, including surgery, radiation therapy, chemotherapy, and targeted drug therapies, employed across various healthcare settings to manage this aggressive and rare cancer. The market's expansion is fundamentally driven by the increasing incidence of angiosarcoma cases globally, necessitating advanced therapeutic interventions. Additionally, sustained investments in research and development, particularly concerning the molecular and genetic underpinnings of angiosarcoma, are propelling the creation of novel targeted therapies. Furthermore, supportive regulatory frameworks, such as orphan drug designations, incentivize pharmaceutical companies to develop treatments for rare conditions.

According to the FDA's 2024 New Drug Therapy Approvals Annual Report, 26 of the 50 novel drug approvals (52%) were for rare or orphan diseases, reflecting the focus on underserved conditions. However, a significant impediment to market expansion remains the persistent lack of standardized treatment protocols for angiosarcoma. Its inherent rarity and heterogeneous nature result in an absence of universally accepted guidelines, leading to considerable variability in patient care across institutions and impeding consistent, high-quality management.

Key Market Drivers

The global angiosarcoma treatment market is significantly influenced by the rising incidence of angiosarcoma cases. This aggressive rare cancer has demonstrated a notable increase in its occurrence, thereby expanding the patient population requiring therapeutic intervention. According to a study published in JAMA Network Open in April 2024, the U. S. incidence of angiosarcoma doubled from 657 newly diagnosed cases in 2001 to 1312 cases in 2019. This upward trend, particularly driven by secondary cases following breast cancer treatment, underscores a growing demand for effective treatment options and diagnostic tools. The dedication of resources towards understanding and combatting rare cancers is evidenced by significant philanthropic contributions; according to Cycle for Survival, in 2024, the community raised $34 million, with 100% allocated to rare cancer research at Memorial Sloan Kettering Cancer Center.

Complementing the increasing patient pool is the critical advancement in targeted therapies and personalized medicine for angiosarcoma. Research efforts are continually uncovering the molecular underpinnings of this heterogeneous disease, leading to the development of more precise and effective treatments. These innovations are shifting the treatment paradigm from broad-spectrum chemotherapy towards specific interventions designed to target cancer cells while minimizing impact on healthy tissue. A notable example of this progress was presented in September 2024, at the European Society for Medical Oncology Congress, where results from a Phase 1 study revealed that the angiosarcoma subtype treated with the investigational drugs botensilimab and balstilimab showed a 39% overall response rate. Such developments are vital for providing viable therapeutic alternatives for patients who often have limited options, directly stimulating market growth as novel treatments reach clinical availability.

Download Free Sample Report

Key Market Challenges

A significant impediment to the expansion of the Global Angiosarcoma Treatment Market is the persistent lack of standardized treatment protocols. The inherent rarity and heterogeneous nature of angiosarcoma contribute to an absence of universally accepted clinical guidelines, resulting in considerable variability in patient care across institutions. This inconsistency directly hampers the development and adoption of advanced therapeutic interventions.

The absence of standardized protocols complicates the design and execution of clinical trials for novel angiosarcoma treatments. Pharmaceutical companies face challenges in establishing uniform patient cohorts and demonstrating clear efficacy across a diverse treatment landscape, thereby prolonging development timelines and increasing research and development costs. According to the Association of Clinical Research Professionals (ACRP), in 2024, 38% of clinical research sites identified the increasing complexity of clinical trials as a top challenge. This complexity is significantly exacerbated in rare and heterogeneous cancers like angiosarcoma due to the non-standardized treatment approaches. The lack of uniform best practices also creates uncertainty for healthcare providers, which can delay the integration of new therapies into clinical practice and impede consistent, high-quality management, ultimately restricting market growth.

Key Market Trends

The expanding application of immunotherapy is a significant trend in the global angiosarcoma treatment market, leveraging the patient's immune system against cancer. This approach is vital for aggressive, rare cancers like angiosarcoma, where traditional therapies often have limited success. Research into tumor immunology has advanced, leading to innovative immune checkpoint inhibitors. For instance, according to a July 2024 article in Targeted Oncology, a Phase 2 study reported in 2023 showed that cabozantinib plus nivolumab achieved a 59% overall response rate in taxane-pretreated advanced angiosarcoma patients. This demonstrates the growing efficacy and broadening utility of immunotherapy, expanding the treatment paradigm and directly driving market growth.

Increased focus on rare cancer drug pipeline development constitutes another critical trend, addressing substantial unmet medical needs. Pharmaceutical companies are committing more resources to novel therapies for these underserved indications. According to the Pharmaceutical Research and Manufacturers of America (PhRMA), in 2024, its member companies invested nearly $101 billion in research and development for complex diseases, with a significant portion targeting rare cancers. This sustained investment strengthens the development pipeline. A key illustration of this focus was, according to a January 2025 article in The Guardian, GSK's acquisition of IDRx, a rare cancer therapy developer, for up to $1.15 billion to enhance its oncology business. These strategic investments and dedicated funding accelerate new therapeutic options, directly fueling market expansion.

Segmental Insights

In the Global Angiosarcoma Treatment Market, immunotherapy stands out as a rapidly expanding segment. This growth is driven by its innovative approach, which harnesses the body's own immune system to specifically identify and eliminate cancer cells. Immunotherapy has demonstrated promising efficacy in clinical trials, particularly in addressing cases resistant to traditional therapies and showing potential for improved patient outcomes. This targeted mechanism offers a more precise and generally less toxic alternative compared to conventional treatments. The ongoing research and continued investigation into immune checkpoint inhibitors by institutions such as the National Cancer Institute further underscore its potential, positioning immunotherapy at the forefront of evolving therapeutic strategies for angiosarcoma.

Regional Insights

North America leads the global angiosarcoma treatment market, primarily driven by its advanced healthcare infrastructure and significant investment in research and development activities. The region benefits from a high prevalence of specialized cancer centers and robust research funding, facilitating early diagnosis and access to innovative oncology treatments. Furthermore, favorable regulatory frameworks, such as those established by the Food and Drug Administration (FDA), support the expedited approval and adoption of novel therapies, including targeted treatments and immunotherapies. This environment fosters increased clinical trial activity and the availability of advanced therapeutic options for patients.

Recent Developments

• In May 2025, Intensity Therapeutics, Inc.'s Phase 3 INVINCIBLE-3 study for its investigational product, INT230-6, was selected for presentation at the American Society of Clinical Oncology Annual Meeting. This ongoing trial focuses on metastatic sarcoma, a category that includes angiosarcoma. INT230-6 is designed to deliver cytotoxic agents directly into tumors, aiming for localized disease control and systemic anti-tumor immune responses. The selection for presentation at a major oncology conference underscores the importance of this research in developing novel therapeutic strategies for advanced sarcomas.

• In October 2024, new data from a phase 1 study (NCT03860272) on the combination of botensilimab and balstilimab were presented at the ESMO Congress, showing durable responses in patients with refractory metastatic sarcoma. This breakthrough research specifically highlighted notable efficacy in the angiosarcoma subgroup, a historically challenging form of cancer to treat. Patients with angiosarcoma showed an overall response rate of 39%, with responses observed in both cutaneous and visceral subtypes. This suggests the potential of this immunotherapy combination to extend treatment possibilities for patients with advanced disease.

• In July 2024, significant advancements were reported regarding an Alliance AO91902 phase 2 clinical trial, which investigated combination immunotherapies for advanced angiosarcoma. Findings from one arm of the study demonstrated that cabozantinib, marketed as Cabometyx, combined with nivolumab, known as Opdivo, exhibited notable anti-tumor activity and favorable tolerability in patients with advanced angiosarcoma previously treated with taxanes. This research highlighted a 62% overall response rate and a median progression-free survival of 9.6 months, representing a crucial development for patients with limited treatment options.

• In May 2024, results from a prospective phase II study were presented at the American Society of Clinical Oncology Annual Meeting, evaluating paclitaxel combined with avelumab as a first-line treatment for unresectable angiosarcoma. The clinical trial enrolled 32 patients with locally advanced or metastatic angiosarcoma who had not received prior systemic treatment. The combination therapy achieved an objective response rate of 50.0%, including one complete response. The median progression-free survival was 6.0 months, indicating a tolerable safety profile and promising efficacy for this aggressive cancer type.

Key Market Players

• Novartis AG
• Bayer AG
• Sanofi AG
• Amgen Inc
• Eli Lilly and Company
• Genentech Inc.
• Janssen Pharmaceuticals
• AbbVie Inc
• Bausch Health Companies Inc.
• GlaxoSmithKline Plc

Report Scope:

In this report, the Global Angiosarcoma Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Angiosarcoma Treatment Market , By Type:

o   Hemangiosarcoma

o   Lymphangiosarcoma

o   Parenchymal Angiosarcoma

• Angiosarcoma Treatment Market , By Treatment:

o   Surgery

o   Radiotherapy

o   Chemotherapy

o   Targeted Therapy

o   Immunotherapy

o   Others

• Angiosarcoma Treatment Market , By End user:

o   Hospital & Clinics

o   Ambulatory Surgical Centers

o   Online Pharmacies

• Angiosarcoma Treatment Market , By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  France

§  United Kingdom

§  Italy

§  Germany

§  Spain

o   Asia Pacific

§  China

§  India

§  Japan

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Angiosarcoma Treatment Market .

Available Customizations:

Global Angiosarcoma Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Angiosarcoma Treatment Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]